Product Description
COLLAGENASE (kohl LAH jen ace) is an enzyme that breaks down collagen in damaged tissue and helps healthy tissue to grow. It may help wounds heal faster. (Sourced from: https://my.clevelandclinic.org/health/drugs/18678-collagenase-ointment)
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical,Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Dominican Republic | Ecuador | Egypt | France | Germany | Hong Kong | Hungary | India | Ireland | Italy | Japan | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Peru | Poland | Portugal | Russia | Slovakia | Slovenia | Spain | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Cellulite
Known Adverse Events: Pain Unspecified | Erythema | Pruritus
Company: Endo
Company Location: DUBLIN 4 L2 00000
Company CEO: Blaise Coleman
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Germany, Italy, Sweden
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Dupuytren Contracture
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RR37_23_01 | P2 |
Unknown Status |
Dupuytren Contracture |
2026-07-31 |
|
| ACTRN12624000664549 | P2 |
Recruiting |
Dupuytren Contracture |
2025-05-17 |
|
| Vibrio alginolyticus collagenase Phase II | P2 |
Active, not recruiting |
Dupuytren Contracture |
2024-02-20 |